Afluria vaccine market seen growing on flu demand and aging population

The Business Research Company says the Afluria vaccine market is set to expand through 2035, driven by seasonal flu outbreaks, broader vaccination coverage and a growing older population. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - The Afluria vaccine market sits inside the broader influenza prevention market, where demand rises with seasonal flu activity and public vaccination campaigns. - Growth in vaccination access, especially through retail pharmacies, could widen uptake and support market expansion through the forecast period. - An aging population matters because older adults face higher risks from influenza complications.

What happened: - The Business Research Company published its Afluria Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 29, 2026. - The report says North America held the largest share of the Afluria market in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - Afluria is an inactivated influenza vaccine for people age 6 months and older. - The vaccine is given by injection and is designed to protect against specific flu strains. - Annual vaccination is advised to maintain immunity during flu season. - Historical market growth has been driven by recurrent seasonal flu outbreaks. - Public health vaccination policies have also supported demand. - Hospital immunization programs have contributed to market growth. - Rising infection-related hospital admissions have added to demand. - Future growth is tied to increased awareness of preventive healthcare. - Broader vaccination coverage goals are expected to support adoption. - The growing availability of retail pharmacy immunization services is another growth factor. - Improvements in cold chain logistics are helping vaccine distribution. - A rising elderly population is adding to demand for influenza vaccination. - The report identifies higher demand for seasonal flu vaccines as a key trend. - Expanded immunization programs for adults and children are another trend. - Stronger government vaccination campaigns are likely to shape the market. - Enhanced vaccine distribution infrastructure is also expected to influence growth.

Between the lines: - The report links market momentum to public-health behavior more than to product changes, which suggests demand will track flu season severity, access points and vaccination policy. - The mention of retail pharmacies and cold chain infrastructure points to distribution, not just clinical need, as a growing driver of vaccine sales. - Flu incidence data cited in the report reinforces the commercial case for vaccination, especially in high-risk groups.

What's next: - The report expects continued market growth through 2035 as prevention-focused care expands. - Demographic pressure from the aging population should keep vaccination demand elevated. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.